Last reviewed · How we verify
GSK2269557 via DPI — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK2269557 via DPI (GSK2269557 via DPI) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK2269557 via DPI TARGET | GSK2269557 via DPI | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK2269557 via DPI CI watch — RSS
- GSK2269557 via DPI CI watch — Atom
- GSK2269557 via DPI CI watch — JSON
- GSK2269557 via DPI alone — RSS
Cite this brief
Drug Landscape (2026). GSK2269557 via DPI — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk2269557-via-dpi. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab